Project 3: Estimating Risk of Ovarian Cancer Ovarian cancer afflicts approximately 26,000 US women per year. More than 70% of these cases will be diagnosed in late stage and the 5-year survival rate for these women remains 20-30%. Though treatment strategies have evolved over time, prevention and early detection hold the greatest potential for reducing the morbidity and mortality of this dread disease. To succeed, research in prevention in prevention and screening requires that we be able to identify populations that are expected to experience large numbers of cases. The more accurately we can target these cases in advance, the more cost-efficient and productive these efforts. Risk-based eligibility has been used successfully in other randomized trials to target individuals most likely to benefit from the intervention. Risk-based screening also holds the potential to increase the positive predictive value of screening and reduce costs. We propose to develop and validate a statistical model for estimating ovarian cancer risk in post-menopausal women using demographic, reproductive, medical and family history data from the Women's Health Initiative using standard failure time models for risk assessment. We will extend this risk model to examine the potential for serum levels of CA-125 and other promising tumor markers to improve on our estimates of risk. These tumor markers will be evaluated in blood specimens collected from cases prior to their diagnosis and in blood cords collected from a sample of similar healthy women using a nested case-control design. The methods of Gail et al for estimating a woman's risk of breast cancer serves as the model for this effort. In addition, we will learn important information about the relationship between various personal characteristics and marker levels within ovarian and between levels of markers and disease characteristics. Validation and analyses will improve our estimates of risk and assist our understanding of the role that tumor markers play in tracking the development of disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083636-03S2
Application #
6502922
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-30
Project End
2002-09-29
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications